Search - tctmd.com

Displaying 281 - 296 of 296

Sort: Relevancy | Date

News Daily News

High Prasugrel Loading Dose Limits Platelet Reactivity after Primary PCI for STEMI

April 09, 2014

News Daily News

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Yael L. Maxwell

February 13, 2014

News Daily News

Hypothermia Does Not Increase Stent Thrombosis Risk in Primary PCI Patients

October 16, 2013

News Daily News

Genetic Alleles Affect Response to Prasugrel in ACS Patients

December 17, 2012

News Daily News

Prasugrel, Ticagrelor Show Delayed Action in STEMI Patients

December 05, 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

Presentation TCT 2012

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

Presenter: Laurent Bonello

October 22, 2012

News Daily News

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

July 10, 2012

News Daily News

PLATO Analysis: PPIs Problematic with Both Ticagrelor, Clopidogrel

March 06, 2012

News Daily News

Study Applies Standardized Bleeding Definition to Disparate Antiplatelet Trials

June 15, 2011

News Daily News

GRAVITAS Published: No Benefit from High-Dose Clopidogrel in Poor Responders

March 15, 2011

PLX Pharma - Aspirin for the Interventionalist: More Than Meets the Eye

CME

Aspirin for the Interventionalist: More Than Meets the Eye

Everyday Antiplatelet Decisions: Making the Right Choices

CME

Everyday Antiplatelet Decisions: Making the Right Choices

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

CME

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

CME

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.